Cardiology
|
March 3, 2025

Understanding the 4 Stages of Congestive Heart Failure

Written By
Dr. Sarah Daglis ND
Medically Reviewed by
Updated On
March 5, 2025

In 2022, congestive heart failure (CHF) accounted for nearly 14% of deaths in the United States. CHF occurs when the heart gradually loses its ability to pump enough blood and oxygen to meet the body's needs.

CHF advances through four distinct stages. This article explores each stage of CHF and evidence-based management strategies recommended by healthcare professionals.

[signup]

What Is Congestive Heart Failure?

Congestive heart failure (CHF), or simply heart failure (HF), is a chronic condition in which the heart cannot pump blood in adequate amounts to meet the body's demands. Despite its name, the heart is still working, though less efficiently.

Common Causes and Risk Factors

There are many causes of heart failure, the most common being coronary artery disease (CAD), causing ischemic heart disease (IHD).

Other medical conditions that may lead to CHF include:

Risk factors for CHF include:

  • Age 65 years or older
  • Substance use, including tobacco, alcohol, and recreational drugs (e.g., cocaine)
  • Sedentary lifestyle
  • High-salt, high-fat diets
  • Personal history of heart issues (e.g., hypertension, CAD, heart attack)
  • Family history of CHF
  • Personal history of chemotherapy known to damage heart muscle

Patients should consult healthcare professionals for guidance on risk management.

Signs and Symptoms of CHF

Symptoms of CHF vary by individual and stage of the condition, with progression typically leading to increased severity.

As the heart struggles to pump, blood builds up in other parts of the body, including the lungs, legs, and feet, causing various symptoms:

  • Shortness of breath
  • Dry cough
  • Chest pain
  • Palpitations
  • Fatigue with exertion
  • Weight gain
  • Swelling in the legs, ankles, and abdomen

As CHF progresses, symptoms typically become more severe.

The Four Stages of Congestive Heart Failure

The American College of Cardiology (ACC) and the American Heart Association (AHA) recognize four stages of CHF. Each stage reflects the progression of heart failure and has corresponding management strategies to improve patient outcomes.

Stage A: At Risk for Heart Failure

Stage A includes individuals at high risk for developing heart failure due to factors like a family history of CHF or the presence of conditions such as hypertension, diabetes, CAD, or other risk factors.

Individuals in Stage A do not manifest symptoms of heart failure and do not have evidence of structural or functional heart disease.

Preventing Progression

Individuals with Stage A heart failure can take proactive steps to reduce their risk of disease progression as guided by their healthcare provider.

Managing preexisting conditions is critical. For example:

  • Patients with hypertension should follow guideline-directed medical therapy (GDMT) to optimize blood pressure control.
  • Those with type 2 diabetes may be prescribed SGLT-2 inhibitors to reduce heart failure-related hospitalizations.
  • Statin therapy may be recommended to manage cholesterol levels.
  • An angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) may be prescribed for patients with CAD, diabetes, high blood pressure, or other conditions.

Lifestyle Changes to Prevent Progression

Lifestyle modifications are also strongly encouraged, including:

Stage B: Pre-Symptomatic Heart Failure 

Individuals in Stage B have no current or past symptoms of heart failure but show evidence of at least one of the following:

  • Structural heart disease: Reduced systolic function, heart chamber enlargement, hypertrophy, valve dysfunction, or abnormal heart motion
  • Increased filling pressure in the heart: Identified through echocardiography or more invasive methods
  • Other risk factors: Elevated B‐type natriuretic peptide (BNP) or persistently high cardiac troponin, excluding competing diagnoses such as chronic kidney disease (CKD), pulmonary embolism (PE), or acute coronary syndrome (ACS)

At this stage, the left ventricle is not functioning optimally. Normally, it receives oxygenated blood from the lungs and pumps it to the rest of the body.

While structural abnormalities may be present, individuals remain asymptomatic.

Diagnostic Tools

In Stage B, the focus is on preventing symptomatic heart failure and reducing the risk of adverse events.

Diagnostic tools include:

  • Echocardiography: Measures left ventricular ejection fraction (LVEF), a measurement of how much blood is pumped with each contraction, and detects structural heart abnormalities.
  • Biomarkers: Elevated BNP or high cardiac troponin levels may indicate increased heart failure risk.
  • Cardiac MRI & CT: These tests provide detailed imaging of structural heart disease.
  • Electrocardiogram (ECG or EKG): Detects arrhythmias or ischemic changes.

Early Intervention

Early intervention strategies at this stage include:

  • ACE Inhibitors (ACEIs): Recommended for patients with reduced ejection fraction (HFrEF), defined as LVEF ≤ 40%, to prevent progression to symptomatic heart failure.
  • Beta-blockers: Essential for patients with HFrEF to prevent the onset of symptoms.
  • Statins and beta-blockers: For patients with HFrEF and a history of ACS or heart attack, combining these medications reduces mortality and prevents worsening HF.
  • Valve and congenital heart disease management: Patients with asymptomatic valvular disease or congenital heart conditions should follow specific guidelines for repair, replacement, or intervention as appropriate.

By implementing these strategies, Stage B patients can delay or prevent the onset of symptomatic HF and reduce cardiovascular risk.

Stage C: Symptomatic Heart Failure

A confirmed diagnosis of heart failure with current or past symptoms characterizes Stage C. Treatment requires a multidisciplinary approach aimed at symptom management, improving survival, and reducing hospitalizations.

Treatment Options and Symptom Management

In addition to the strategies for Stage A and Stage B, the following pharmacological therapies are recommended for patients with HFrEF in Stage C:

  • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone, for example, may be prescribed to reduce morbidity and mortality.
  • Hydralazine and Isosorbide Dinitrate: Recommended for African American patients if other treatments fail.
  • Ivabradine: Slows heart rate in patients with HR >70 bpm (beats per minute) with persistent symptoms.
  • Vericiguat: A guanylate cyclase stimulator may be considered for patients with recent heart failure events under the supervision of a cardiologist.
  • Implantable Cardioverter-Defibrillator (ICD): Considered for patients at high risk of life-threatening arrhythmias.

Additional aspects of care include:

  • Patient Education: Teach patients about their condition and self-management.
  • Social Support: Encourage family or community support systems.
  • Vaccination: Prevent respiratory illnesses through immunization.
  • Diuretics: Manage fluid retention as needed.

By integrating these strategies, the progression of heart failure can be slowed, hospitalizations reduced, and patient outcomes improved.

Stage D: Advanced Heart Failure

Stage D represents advanced heart failure, where symptoms significantly impact daily life despite aggressive treatment. 

Patients may experience recurrent hospitalizations, and their reduced ejection fraction typically does not improve with standard treatments.

Palliative Care and Advanced Therapies

Management in Stage D includes treatments from earlier stages and may involve advanced therapies such as:

The goal in Stage D is to improve quality of life, manage symptoms, and provide comfort when curative treatments are no longer effective.

Managing Congestive Heart Failure at Every Stage

Managing CHF requires a multifaceted approach. Always consult a medical professional for the most appropriate regimen.

Medical Interventions and Treatments

Medications are critical at all stages of heart failure to manage symptoms, slow progression, and improve survival. The choice of drugs depends on underlying conditions, HF stage, treatment goal, and personalized factors.

Lifestyle Modifications

Lifestyle changes can have profound impacts on heart failure management. These include:

  • A heart-healthy, low-sodium diet, such as the Mediterranean or DASH diet, may be beneficial. Consult your provider for personalized dietary guidance.
  • Regular physical activity can support heart health. Seek advice from your provider for safe exercise practices.
  • Stress management, such as mindfulness, yoga, or other modalities, can support cardiovascular wellness.

Monitoring and Regular Check-ups

Ongoing monitoring of symptoms is critical to managing heart failure effectively. 

Regular check-ups with healthcare providers help track progression, adjust treatment plans, and prevent complications. 

Patients should also be vigilant in monitoring symptoms like shortness of breath, swelling, and fatigue, promptly reporting any changes to their healthcare team.

Addressing Myths and Misconceptions About CHF

There are several myths and misconceptions surrounding heart failure. Let's clear them up:

Heart failure means your heart has stopped beating.

Heart failure does not mean the heart has stopped beating. It is a chronic condition where the heart cannot pump enough blood to meet the body's needs.

Heart failure cannot be treated.

Heart failure is manageable with medical treatment and lifestyle modifications. Various options exist to help control symptoms and slow progression. Talk to your doctor about the best options for you.

If you have heart failure, you shouldn't exercise.

Regular physical activity is crucial for those with heart failure as it helps strengthen the heart and improve circulation. However, it's important not to overdo it—consult your doctor for personalized exercise guidelines.

Heart failure is inevitable as you age.

Although heart failure is more prevalent among older adults, it is not a guaranteed consequence of aging. You can reduce risk by maintaining a healthy lifestyle and seeking early treatment.

A heart failure diagnosis means you will die soon.

Many people with heart failure lead normal, fulfilling lives. The outlook varies depending on many factors, and with proper management, life expectancy and quality of life can be significantly improved.

[signup]

Key Takeaways

  • Congestive heart failure (CHF) is a chronic and progressive condition in which the heart cannot pump blood in adequate amounts to meet the body's demands.
  • It progresses through four stages:
    • Stage A: At risk for heart failure without symptoms or structural disease.
    • Stage B: Pre-symptomatic heart failure with evidence of structural heart disease.
    • Stage C: Symptomatic heart failure requiring comprehensive management.
    • Stage D: Advanced heart failure with severe symptoms, often requiring advanced treatments.
  • Effective management at every stage includes a combination of medical interventions, lifestyle modifications, and regular monitoring to improve outcomes and quality of life.
  • Early detection and proactive management are critical in slowing the progression of CHF, reducing hospitalizations, and enhancing the quality of life for those affected. 
  • Individuals can manage the condition more effectively by addressing risk factors and adhering to treatment plans.
  • If you or someone you know is at risk for or diagnosed with heart failure, consult a healthcare professional for personalized advice.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. American Heart Association. (2016). Implantable Cardioverter Defibrillator (ICD). Www.heart.org. https://www.heart.org/en/health-topics/arrhythmia/prevention--treatment-of-arrhythmia/implantable-cardioverter-defibrillator-icd
  2. American Heart Association. (2021, June 21). Stress and heart health. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/stress-management/stress-and-heart-health
  3. American Heart Association. (2022a, April 2). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Professional.heart.org. https://professional.heart.org/en/science-news/2022-guideline-for-the-management-of-heart-failure
  4. American Heart Association. (2022b, December 5). Silent Ischemia and Ischemic Heart Disease. Www.heart.org. https://www.heart.org/en/health-topics/heart-attack/about-heart-attacks/silent-ischemia-and-ischemic-heart-disease
  5. American Heart Association. (2023). Ejection fraction heart failure measurement. Www.heart.org; American Heart Association. https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement
  6. Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O'Connor, C. M. (2020). Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 382(20), 1883–1893. https://doi.org/10.1056/nejmoa1915928
  7. Berman, M. N., & Bhardwaj, A. (2022). Physiology, left ventricular function. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK541098/
  8. Bryant, A. (2025, February 12). Pulmonary Embolism: Causes, Symptoms and Treatment. Rupa Health. https://www.rupahealth.com/post/pulmonary-embolism-causes-symptoms-and-treatment
  9. CDC. (2019, February 26). Vaccination Information for Adults with Heart Disease | CDC. Www.cdc.gov. https://www.cdc.gov/vaccines/adults/rec-vac/heart-disease-home.html
  10. Centers for Disease Control and Prevention. (2024, April 29). About heart failure. CDC.gov. https://www.cdc.gov/heart-disease/about/heart-failure.html
  11. Cleveland Clinic. (2022, April 29). Heart & Blood Vessels: Heart Blood Flow | Cleveland Clinic. Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/articles/17060-how-does-the-blood-flow-through-your-heart
  12. Cleveland Clinic. (2023, March 10). Congestive Heart Failure. Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/17069-heart-failure-understanding-heart-failure
  13. Cloyd, J. (2022, September 16). 9 Health Benefits of the DASH Diet. Www.rupahealth.com. https://www.rupahealth.com/post/9-health-benefits-of-the-dash-diet
  14. Cloyd, J. (2023a, April 10). A Functional Medicine Hypertension Protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-hypertension-protocol
  15. Cloyd, J. (2023b, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease
  16. Cloyd, J. (2023c, October 9). Rhythms of the Heart: Demystifying Common Types of Heart Arrhythmia. Rupa Health. https://www.rupahealth.com/post/rhythms-of-the-heart-demystifying-common-types-of-heart-arrhythmia
  17. Cloyd, J. (2024a, January 26). Cardiac Risk Assessment: When to Utilize Troponin and NT-proBNP Tests. Rupa Health. https://www.rupahealth.com/post/cardiac-risk-assessment-when-to-utilize-troponin-and-nt-probnp-tests
  18. Cloyd, J. (2024b, June 20). Understanding Heart Palpitations: Causes, Diagnosis, and Treatment. Rupa Health. https://www.rupahealth.com/post/understanding-heart-palpitations-causes-diagnosis-and-treatment
  19. Cloyd, J. (2024c, December 16). 6 Warning Signs of a Heart Attack a Month Before It Happens. Rupa Health. https://www.rupahealth.com/post/6-potential-warning-signs-of-a-heart-attack-before-it-happens
  20. Cloyd, J. (2025, January 21). How Furosemide Works: Benefits and Risks for Patients. Rupa Health. https://www.rupahealth.com/post/how-furosemide-works-benefits-and-risks-for-patients
  21. Daglis, S. (2024, August 7). Tachycardia: Don't Let Your Heart Run Away with You. Rupa Health. https://www.rupahealth.com/post/tachycardia-dont-let-your-heart-run-away-with-you
  22. Daglis, S. (Ed.). (2024, November 8). 10 Lab Tests For Patients With A Family History of Chronic Kidney Disease. Rupa Health. https://www.rupahealth.com/post/10-lab-tests-for-patients-with-a-family-history-of-chronic-kidney-disease
  23. DePorto, T. (2023, January 10). Timeline: What Happens Inside Your Body When You Quit Smoking? Rupa Health. https://www.rupahealth.com/post/what-happens-to-our-bodies-when-we-quit-smoking-a-timeline
  24. European Society of Cardiology. (2024, June 4). Myths and Facts About Heart Failure. Heart Failure Matters. https://www.heartfailurematters.org/understanding-heart-failure/myths-and-facts-about-heart-failure/
  25. Farzam, K., & Jan, A. (2023, August 22). Beta Blockers. National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532906/
  26. Ferreira, J. P., Pitt, B., & Zannad, F. (2024). Mineralocorticoid Receptor Antagonists in Heart Failure: An Update. Circulation: Heart Failure, 17(12). https://doi.org/10.1161/circheartfailure.124.011629
  27. Gentile, P., Masciocco, G., Palazzini, M., Tedeschi, A., Ruzzenenti, G., Conti, N., D’Angelo, L., Foti, G., Perna, E., Verde, A., Ammirati, E., Sinagra, G., Oliva, F., & Garascia, A. (2023). Intravenous continuous home inotropic therapy in advanced heart failure: Insights from an observational retrospective study. European Journal of Internal Medicine, 116, 65–71. https://doi.org/10.1016/j.ejim.2023.06.010
  28. Goyal, A., Cusick, A. S., & Bansal, P. (2023, August 17). Peripheral Edema. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554452/
  29. Heart Failure Society of America. (2025). Understand Heart Failure - and Know Your Risk | HFSA. Hfsa.org. https://hfsa.org/understand-heart-failure-and-know-your-risk
  30. Herman, L., & Bashir, K. (2023, July 31). Angiotensin Converting Enzyme Inhibitors (ACEI). National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK431051/
  31. Hill, R. D., & Vaidya, P. N. (2023, March 27). Angiotensin II receptor blockers (ARB). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537027/
  32. Kosaraju, A., & Makaryus, A. N. (2023, April 24). Left Ventricular Ejection Fraction. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459131/
  33. Malik, A., Brito, D., Vaqar, S., & Chhabra, L. (2023). Congestive Heart Failure. National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430873/
  34. Mayo Clinic. (2019). Ventricular assist device (VAD) - Mayo Clinic. Mayoclinic.org. https://www.mayoclinic.org/tests-procedures/ventricular-assist-device/about/pac-20384529
  35. Mayo Clinic. (2023, January 31). Echocardiogram. Mayoclinic.org. https://www.mayoclinic.org/tests-procedures/echocardiogram/about/pac-20393856
  36. Mayo Clinic. (2024, April 2). Electrocardiogram (ECG or EKG). Mayoclinic.org; Mayo Clinic. https://www.mayoclinic.org/tests-procedures/ekg/about/pac-20384983
  37. Morris, J. H., & Chen, L. (2019). Exercise Training and Heart Failure: A Review of the Literature. Cardiac Failure Review, 5(1), 57. https://doi.org/10.15420/cfr.2018.31.1
  38. National Cancer Institute. (2018, September 21). Investigating the Cardiac Side Effects of Cancer Treatments. National Cancer Institute; Cancer.gov. https://www.cancer.gov/news-events/cancer-currents-blog/2018/cancer-treatment-heart-side-effects
  39. Padda, I. S., Mahtani, A. U., & Parmar, M. (2023, June 3). Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK576405/
  40. Penn Medicine. (2022, July 18). 5 Scary Myths about Heart Failure - Penn Medicine. Www.pennmedicine.org. https://www.pennmedicine.org/updates/blogs/heart-and-vascular-blog/2015/may/5-scary-myths-about-heart-failure
  41. Rupa Health. (n.d.). Sodium. Rupa Health. https://www.rupahealth.com/biomarkers/sodium
  42. Sizar, O., Khare, S., Jamil, R. T., & Talati, R. (2024, February 29). Statin Medications. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430940/
  43. SKY, R. S. (2004). Statins, Beta Blockers Improve Outcomes After MI with CHF. American Family Physician, 70(9), 1774–1776. https://www.aafp.org/pubs/afp/issues/2004/1101/p1774.html
  44. Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., Khairy, P., Landzberg, M. J., Saidi, A., Valente, A. M., & Van Hare, G. F. (2019). 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(14). https://doi.org/10.1161/cir.0000000000000603
  45. Sweetnich, J. (2023, April 25). Complementary and Integrative Medicine Approaches to Type 2 Diabetes Management. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-approaches-to-type-2-diabetes-management
  46. UCSF Health. (2019, March 14). Diet and Congestive Heart Failure. Ucsfhealth.org; UCSF Health. https://www.ucsfhealth.org/education/diet-and-congestive-heart-failure
  47. Vyas, A., & Nirmal Onteddu. (2022, February 16). Vericiguat. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK574528/
  48. Weinberg, J. (2022, November 16). 4 Science Backed Health Benefits of The Mediterranean Diet. Rupa Health. https://www.rupahealth.com/post/4-science-backed-health-benefits-of-the-mediterranean-diet
  49. Yoshimura, H. (2024a, April 12). Nutritional interventions in heart failure care. Rupa Health. https://www.rupahealth.com/post/nutritional-interventions-in-heart-failure-care
  50. Yoshimura, H. (2024b, May 31). Exercise Protocols for Cardiac Rehabilitation and Heart Failure. Rupa Health. https://www.rupahealth.com/post/exercise-protocols-for-cardiac-rehabilitation-and-heart-failure
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Cardiology
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.